Zhi Tong Cai Jing·2025-11-27 05:49Core Viewpoint - Rongchang Biologics (09995) experienced a significant stock increase, rising over 7% in the afternoon trading session, with a current price of 90.75 HKD and a trading volume of 319 million HKD, driven by positive clinical research news regarding its product candidates [1] Group 1: Clinical Research Developments - At the 2025 ESMO annual meeting, the clinical study results for Vidisicimab combined with Toripalimab versus chemotherapy for first-line treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma were released, indicating a major shift in the treatment landscape for urothelial carcinoma [1] - Yongxing Securities reported that the combination therapy of Vidisicimab shows excellent immunotherapy efficacy, marking a significant change in the treatment paradigm for urothelial carcinoma [1] Group 2: Product Pipeline and Market Potential - CITIC Construction Investment (601066) highlighted that in 2025, the core product Taitasip will rapidly expand after receiving approval for new indications, and the data for the combination treatment of Vidisicimab is promising [1] - The application for the market approval of RC28 for DME indication has been accepted, and the investigational pipeline includes RC148, which has received breakthrough therapy designation, with continuous validation of its clinical data [1] - Overall, the company is accelerating its commercialization process and has a well-structured pipeline, indicating a positive outlook for future development [1]